Cargando…
Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study
BACKGROUND: Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia. The etiology underlying AF is still largely unknown. At the intersection of the innate immune system and hemostasis, immunothrombosis may be a possible cause of atrial remodeling, and therefore be an underlying c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766396/ https://www.ncbi.nlm.nih.gov/pubmed/34559294 http://dx.doi.org/10.1007/s00392-021-01938-4 |
_version_ | 1784634520635441152 |
---|---|
author | Tilly, Martijn J. Geurts, Sven Donkel, Samantha J. Ikram, M. Arfan de Groot, Natasja M. S. de Maat, Moniek P. M. Kavousi, Maryam |
author_facet | Tilly, Martijn J. Geurts, Sven Donkel, Samantha J. Ikram, M. Arfan de Groot, Natasja M. S. de Maat, Moniek P. M. Kavousi, Maryam |
author_sort | Tilly, Martijn J. |
collection | PubMed |
description | BACKGROUND: Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia. The etiology underlying AF is still largely unknown. At the intersection of the innate immune system and hemostasis, immunothrombosis may be a possible cause of atrial remodeling, and therefore be an underlying cause of AF. METHODS: From 1990 to 2014, we followed participants aged 55 and over, free from AF at inclusion. Immunothrombosis factors fibrinogen, von Willebrand factor, ADAMTS13, and neutrophil extracellular traps (NETs) levels were measured at baseline. Participants were followed until either onset of AF, loss-to-follow-up, or reaching the end-date of 01-01-2014. Cox proportional hazard modelling was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for cardiovascular risk factors. RESULTS: We followed 6174 participants (mean age 69.1 years, 57% women) for a median follow-up time of 12.8 years. 364 men (13.7%, incidence rate 13.0/1000 person-years) and 365 women (10.4%, incidence rate 8.9/1000 person-years) developed AF. We found no significant association between markers of immunothrombosis and new-onset AF after adjusting for cardiovascular risk factors [HR 1.00 (95% CI 0.93–1.08) for fibrinogen, 1.04 (0.97–1.12) for von Willebrand factor, 1.00 (1.00–1.01) for ADAMTS13, and 1.01 (0.94–1.09) for NETs]. In addition, we found no differences in associations between men and women. CONCLUSION: We found no associations between markers of immunothrombosis and new-onset AF in the general population. Inflammation and immunothrombosis may be associated with AF through other cardiovascular risk factors or predisposing conditions of AF. Our findings challenge the added value of biomarkers in AF risk prediction. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01938-4. |
format | Online Article Text |
id | pubmed-8766396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-87663962022-02-02 Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study Tilly, Martijn J. Geurts, Sven Donkel, Samantha J. Ikram, M. Arfan de Groot, Natasja M. S. de Maat, Moniek P. M. Kavousi, Maryam Clin Res Cardiol Original Paper BACKGROUND: Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia. The etiology underlying AF is still largely unknown. At the intersection of the innate immune system and hemostasis, immunothrombosis may be a possible cause of atrial remodeling, and therefore be an underlying cause of AF. METHODS: From 1990 to 2014, we followed participants aged 55 and over, free from AF at inclusion. Immunothrombosis factors fibrinogen, von Willebrand factor, ADAMTS13, and neutrophil extracellular traps (NETs) levels were measured at baseline. Participants were followed until either onset of AF, loss-to-follow-up, or reaching the end-date of 01-01-2014. Cox proportional hazard modelling was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for cardiovascular risk factors. RESULTS: We followed 6174 participants (mean age 69.1 years, 57% women) for a median follow-up time of 12.8 years. 364 men (13.7%, incidence rate 13.0/1000 person-years) and 365 women (10.4%, incidence rate 8.9/1000 person-years) developed AF. We found no significant association between markers of immunothrombosis and new-onset AF after adjusting for cardiovascular risk factors [HR 1.00 (95% CI 0.93–1.08) for fibrinogen, 1.04 (0.97–1.12) for von Willebrand factor, 1.00 (1.00–1.01) for ADAMTS13, and 1.01 (0.94–1.09) for NETs]. In addition, we found no differences in associations between men and women. CONCLUSION: We found no associations between markers of immunothrombosis and new-onset AF in the general population. Inflammation and immunothrombosis may be associated with AF through other cardiovascular risk factors or predisposing conditions of AF. Our findings challenge the added value of biomarkers in AF risk prediction. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01938-4. Springer Berlin Heidelberg 2021-09-24 2022 /pmc/articles/PMC8766396/ /pubmed/34559294 http://dx.doi.org/10.1007/s00392-021-01938-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Tilly, Martijn J. Geurts, Sven Donkel, Samantha J. Ikram, M. Arfan de Groot, Natasja M. S. de Maat, Moniek P. M. Kavousi, Maryam Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study |
title | Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study |
title_full | Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study |
title_fullStr | Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study |
title_full_unstemmed | Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study |
title_short | Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study |
title_sort | immunothrombosis and new-onset atrial fibrillation in the general population: the rotterdam study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766396/ https://www.ncbi.nlm.nih.gov/pubmed/34559294 http://dx.doi.org/10.1007/s00392-021-01938-4 |
work_keys_str_mv | AT tillymartijnj immunothrombosisandnewonsetatrialfibrillationinthegeneralpopulationtherotterdamstudy AT geurtssven immunothrombosisandnewonsetatrialfibrillationinthegeneralpopulationtherotterdamstudy AT donkelsamanthaj immunothrombosisandnewonsetatrialfibrillationinthegeneralpopulationtherotterdamstudy AT ikrammarfan immunothrombosisandnewonsetatrialfibrillationinthegeneralpopulationtherotterdamstudy AT degrootnatasjams immunothrombosisandnewonsetatrialfibrillationinthegeneralpopulationtherotterdamstudy AT demaatmoniekpm immunothrombosisandnewonsetatrialfibrillationinthegeneralpopulationtherotterdamstudy AT kavousimaryam immunothrombosisandnewonsetatrialfibrillationinthegeneralpopulationtherotterdamstudy |